BRIEF-Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile

Biohaven

Biohaven

BHVN

0.00

May 26 (Reuters) - Biohaven Ltd BHVN.N:

  • BIOHAVEN REPORTS NEW CLINICAL DATA IN EPILEPSY WITH OPAKALIM, A SELECTIVE KV7.2/7.3 ACTIVATOR, HIGHLIGHTING SEIZURE CONTROL AND MARKEDLY DIFFERENTIATED TOLERABILITY PROFILE

  • BIOHAVEN LTD - OPAKALIM PROLONGS MEDIAN TIME TO SECOND SEIZURE TO 141 DAYS VERSUS. 47 DAYS FOR PLACEBO

  • BIOHAVEN LTD - ON TRACK FOR TOP-LINE PHASE 2/3 RESULTS IN REFRACTORY FOCAL EPILEPSY IN 2H 2026

Source text: ID:nPn95Tlwda

Further company coverage: BHVN.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.